242 related articles for article (PubMed ID: 18166299)
1. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
Rizzo M; Berneis K; Carmina E; Rini GB
Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299
[TBL] [Abstract][Full Text] [Related]
2. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
[TBL] [Abstract][Full Text] [Related]
3. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
4. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
Doi SA; Abbas JM; Parkinson L; Chakraborty J; Akanji AO
Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
[TBL] [Abstract][Full Text] [Related]
5. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
6. Management of dyslipidemia in diabetes.
Solano MP; Goldberg RB
Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
8. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
[TBL] [Abstract][Full Text] [Related]
9. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
10. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
11. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
12. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Davidson M
Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
[TBL] [Abstract][Full Text] [Related]
13. Who needs to care about small, dense low-density lipoproteins?
Rizzo M; Berneis K
Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554
[TBL] [Abstract][Full Text] [Related]
14. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of isolated low high-density lipoprotein syndrome.
Bermúdez V; Cano R; Cano C; Bermúdez F; Arraiz N; Acosta L; Finol F; Pabón MR; Amell A; Reyna N; Hidalgo J; Kendall P; Manuel V; Hernández R
Am J Ther; 2008; 15(4):377-88. PubMed ID: 18645343
[TBL] [Abstract][Full Text] [Related]
16. Lipid abnormalities and cardiovascular risk in the elderly.
Milionis HJ; Elisaf MS; Mikhailidis DP
Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
[TBL] [Abstract][Full Text] [Related]
17. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
Ghandehari H; Kamal-Bahl S; Wong ND
Am Heart J; 2008 Jul; 156(1):112-9. PubMed ID: 18585505
[TBL] [Abstract][Full Text] [Related]
19. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
20. The predictive role of atherogenic dyslipidemia in subjects with non-coronary atherosclerosis.
Berneis K; Rizzo M; Spinas GA; Di Lorenzo G; Di Fede G; Pepe I; Pernice V; Rini GB
Clin Chim Acta; 2009 Aug; 406(1-2):36-40. PubMed ID: 19433079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
